OncoMatch/Clinical Trials/NCT05351788
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Is NCT05351788 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SKB264 and KL-A167 for non-small cell lung cancer.
Treatment: SKB264 · KL-A167 · Carboplatin · Cisplatin — The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: ALK wild-type
Required: EGFR activating mutation
Required: EGFR wild-type
Disease stage
Metastatic disease required
Patients with locally advanced/metastatic NSCLC; at least one measurable lesion per RECIST v1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor — advanced or metastatic
who have failed previous treatment with EGFR-TKIs
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05351788 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received EGFR tyrosine kinase inhibitor.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR activating mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages